» Articles » PMID: 11841899

Retention Rate and Illicit Opioid Use During Methadone Maintenance Interventions: a Meta-analysis

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2002 Feb 14
PMID 11841899
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of methadone maintenance in opioid addiction was assessed in terms of programme retention rate and reduction of illicit opioid use by means of a meta-analysis of randomised, controlled and double blind clinical trials. The results were compared with interventions using buprenorphine and levo-acetylmethadol (LAAM). Trials were identified from the PubMed database from 1966 to December 1999 using the major medical subject headings 'methadone' and 'randomised controlled trial'. Data for a total of 1944 opioid-dependent patients from 13 studies were analysed. Sixty-four percent of patients received methadone, administered either as fixed or adjusted doses. Thus, 890 patients received > or = 50 mg/day (high dose group) and 392 were given < 50 mg/day (low dose group). Of 662 controls, 131 received placebo, 350 buprenorphine (265 at doses > or = 8 mg/day and 85 at doses < 8 mg/day) and 181 LAAM. High doses of methadone were more effective than low doses in the reduction of illicit opioid use (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.26--2.36). High doses of methadone were significantly more effective than low doses of buprenorphine (< 8 mg/day) for retention rates and illicit opioid use, but similar to high doses of buprenorphine (> or = 8 mg/day) for both parameters. Patients treated with LAAM had more risk of failure of retention than those receiving high doses of methadone (OR 1.92, 95% CI 1.32--2.78). It is proposed that in agonist-maintenance programmes, oral methadone at doses of 50 mg/day or higher is the drug of choice for opioid dependence.

Citing Articles

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.

Bouthillier A, Bastien G, McAnulty C, Bakouni H, Le Foll B, Socias M Harm Reduct J. 2025; 22(1):14.

PMID: 39923043 PMC: 11806552. DOI: 10.1186/s12954-025-01157-4.


Disclosing Recovery: A pilot randomized controlled trial of a patient decision aid to improve disclosure processes for people in treatment for opioid use disorder.

Earnshaw V, Sepucha K, Laurenceau J, Subramanian S, Hill E, Wallace J J Subst Use Addict Treat. 2024; 160:209291.

PMID: 38272118 PMC: 11060902. DOI: 10.1016/j.josat.2024.209291.


Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study.

Williams A, Krawczyk N, Hu M, Harpel L, Aydinoglo N, Cerda M Lancet Reg Health Am. 2023; 28:100636.

PMID: 38152421 PMC: 10751716. DOI: 10.1016/j.lana.2023.100636.


Impact of California Statute on Naloxone Availability and Opioid Overdose Rates.

Gallant T, Gilbert A, Zargham S, Lorenzo M, Puglisi J, Nicholas Z AJPM Focus. 2023; 2(3):100112.

PMID: 37790675 PMC: 10546523. DOI: 10.1016/j.focus.2023.100112.


Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes.

Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T CMAJ. 2023; 195(19):E668-E676.

PMID: 37188370 PMC: 10185363. DOI: 10.1503/cmaj.221550.